Top Suppliers:I want be here
Related CAS#:
93106-60-6 1173021-92-5
266346-15-0 931066-01-2
131775-99-0 112732-17-9
93106-59-3 116169-42-7
528851-31-2 1040662-32-5
1158522-08-7 940364-43-2
134104-43-1 946223-30-9
131615-57-1 6906-52-1
930439-75-1 1018584-77-4
1040656-66-3

93106-60-6

93106-60-6 structure
93106-60-6 structure
  • Name: Enrofloxacin
  • Chemical Name: enrofloxacin
  • CAS Number: 93106-60-6
  • Molecular Formula: C19H22FN3O3
  • Molecular Weight: 359.395
  • Catalog: API Antibiotics Other antibiotics
  • Create Date: 2018-02-07 08:00:00
  • Modify Date: 2024-01-02 10:26:31
  • Enrofloxacin is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis.
Name enrofloxacin
Synonyms bayvp2674
Enorfloxacin
Enrolfoxacin
1-cyclopropyl-7-(4-ethyl-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid
cfpq
Enrofoxacin
Enrofloxacin
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethyl-1-piperazinyl)-quinoline-3-carboxylic acid
1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
ROFLOXACIN BASE
MFCD01861684
Baytri
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethyl-1-piperazinyl)-3-quinolinecarboxylic acid
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethylpiperazino)-quinoline-3-carboxylic acid
Description Enrofloxacin is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis.
Related Catalog
Target

MIC90: 0.312 μg/mL ( Mycoplasma bovis)[1]

In Vitro Mycoplasma bovis is a worldwide pathogen, causative agent of pneumonia, mastitis, arthritis, and a variety of other symptoms in cattle. The antibiotic susceptibility profiles of the Hungarian strains are consistent within the tested group of fluoroquinolones. Three isolates (MYC44, MYC45 and MYC46) have high MIC values (≥10 μg/mL) to Enrofloxacin, while the rest of the strains are inhibited by Enrofloxacin with MICs ≤0.312 or 0.625 μg/mL[1].
In Vivo Mice (n=80) undergo transient middle cerebral artery occlusion (MCAo) with reperfusion after 60 minutes. After MCAo, animals are randomly assigned to receive either a daily preventive medication (n=26, Enrofloxacin) starting at the day of MCAo or a therapeutic medication (n=25; Enrofloxacin) after diagnosis of lung infection. Standard treatment started immediately after the appearance of clinical signs (general health score>6) usually between day 4 and 6 after stroke. Both, preventive and standard antibiotic treatment using Enrofloxacin improve survival in a similar way compared with placebo treatment[2].
Animal Admin Mice[2] 11- to 14-week-old C57Bl6/J male mice are used. Enrofloxacin (2.5% oral solution) is dispensed in saline (2 mg/mL), antibiotic-treated animals receive a daily orally dispensed dose of 10 mg/kg body weight via feeding needle every 12 hours over a period of 7 days, while placebo animals receive the same amount of saline via feeding needle. Animals of preventive antibiotic group obtained Enrofloxacin after waking from reperfusion anesthesia (ca. 1 hour after operation). Therapeutic antibiotic treatment is given immediately after appearance of clinical signs (general health score>5) and confirmation of lung infection by MRI (signal rate≥5%). The group allocation is randomized[2].
References

[1]. Sulyok KM, et al.Antibiotic susceptibility profiles of Mycoplasma bovis strains isolated from cattle in Hungary, Central Europe. BMC Vet Res. 2014 Oct 25;10:256.

[2]. Hetze S, et al. Superiority of preventive antibiotic treatment compared with standard treatment of poststroke pneumonia in experimental stroke: a bed to bench approach. J Cereb Blood Flow Metab. 2013 Jun;33(6):846-54.
Density 1.4±0.1 g/cm3
Boiling Point 560.5±50.0 °C at 760 mmHg
Melting Point 225 °C
Molecular Formula C19H22FN3O3
Molecular Weight 359.395
Flash Point 292.8±30.1 °C
Exact Mass 359.164520
PSA 65.78000
LogP 1.88
Vapour Pressure 0.0±1.6 mmHg at 25°C
Index of Refraction 1.634
Storage condition -20°C Freezer

CHEMICAL IDENTIFICATION

RTECS NUMBER :
VB1993650
CHEMICAL NAME :
3-Quinolinecarboxylic acid, 1,4-dihydro-1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6 -fluoro- 4-oxo-
CAS REGISTRY NUMBER :
93106-60-6
LAST UPDATED :
199612
DATA ITEMS CITED :
5
MOLECULAR FORMULA :
C19-H22-F-N3-O3
MOLECULAR WEIGHT :
359.44

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
5 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
4336 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
200 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

MUTATION DATA

TYPE OF TEST :
Mutation in microorganisms
TEST SYSTEM :
Bacteria - Salmonella typhimurium
DOSE/DURATION :
60 ng/plate
REFERENCE :
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 248,135,1991
Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Hazard Codes Xi: Irritant;
Risk Phrases R36/37/38
Safety Phrases 26-36/37
RIDADR NONH for all modes of transport
WGK Germany 3
RTECS VB1993650

Chemsrc provides CAS#:93106-60-6 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 93106-60-6 | Chemsrc address: https://m.chemsrc.com/en/baike/749573.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved